Novonesis A/s Class B · OMXCOP:NSIS_B
Novonesis A/s Class B — Novonesis A S — Q1 2024 Earnings Presentation
13 slides from Novonesis A/s Class B's earnings presentation, May 3, 2024
Slide 1: Conference call Trading statement Q1 2024
May 3, 2024 Conference call Trading statement Q1 2024
Slide 2: Forward-looking statement
Forward-looking statement Disclaimer This announcement includes forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of the combined group and all of which are based on the combined group's current belief
Slide 3: 4% organic sales growth in line with expectations; outlook maintained
4% organic sales growth in line with Sales and organic sales growth y/y, mEUR expectations; outlook maintained Planetary Health 44% Biosolutions 56% Sales performance Q1 2024 Food & Health • Organic sales growth of 4% (volume ~2%; pricing ~2%) Biosolutions +4% +6% • Emerging markets 14%; Developed m
Slide 4: Food & Health Biosolutions
Human Health 25% Food & Health Biosolutions Sales and organic sales growth, Food & Health Biosolutions y/y 75% mEUR +3% +3% Food & Beverages Sales performance Q1 2024 • Organic sales growth of 3% 424.8 432.8 • Growth driven by Food & Beverages • Human Health with a soft start to the year as expected
Slide 5: Food & Health Biosolutions: Food & Beverages
Food & Health Biosolutions: Sales and organic sales growth, Food & Beverages y/y Food & Beverages mEUR +6% +2% Sales performance Q1 2024 317.4 318.6 • Organic sales growth of 6% • Driven by strong Dairy, solid Baking, and softer Beverages • Destocking impacting last year has levelled off Q1 2024 Q1
Slide 6: Food & Health Biosolutions: Human Health
Food & Health Biosolutions: Sales and organic sales growth, Human Health y/y Human Health mEUR -5% +5% Sales performance Q1 2024 • Organic sales performance of -5% in line with expectations 107.4 114.2 • Decline due to a strong comparable and order timing in HMO and Dietary supplements Q1 2024 Q1 20
Slide 7: Planetary Health Biosolutions
Household Care 35% Planetary Health Biosolutions Sales and organic sales growth, 65% Planetary Health Biosolutions y/y mEUR +5% +9% Agriculture, Energy & Tech Sales performance Q1 2024 • Organic sales growth of 5% 540.7 523.7 • Growth driven by Household Care • Agriculture, Energy & Tech at flat per
Slide 8: Planetary Health Biosolutions: Household Care
Planetary Health Biosolutions: Sales and organic sales growth, Household Care y/y Household Care mEUR +15% +2% Sales performance Q1 2024 • Organic sales growth of 15% 191.9 168.9 • Double-digit growth driven by all regions from increased penetration and innovation including timing Q1 2024 Q1 2023 •
Slide 9: Planetary Health Biosolutions: Agriculture, Energy & Tech
Planetary Health Biosolutions: Sales and organic sales growth, Agriculture, Energy & Tech y/y Agriculture, Energy & Tech mEUR +0% +13% Sales performance Q1 2024 • Organic sales performance flat 348.8 354.8 • Demanding comparable in Animal Nutrition due to order timing and softer Plant due to continu
Slide 10: Outlook 2024
Outlook 2024 • Divestment of part of the lactase enzyme business finalized • Organic sales growth of 5-7% driven predominately by volume • Adjusted EBITDA margin of ~35% • Gross margin expected to strengthen over 2023 Outlook 2024¹ Organic sales growth 5-7% Adj. EBITDA margin ~35% For modeling purpo
Slide 11: Summary
Summary • Organic sales growth in line with expectations • Outlook 2024 maintained • Integration progressing as planned • Upcoming event: Capital Markets Day in Central London on June 18, 2024 11
Slide 12: hovonesis
hovonesis
Slide 13: Organic sales performance by region
Organic sales performance by region North America Developed markets Q1 y/y: -1% Q1 y/y: -1% Europe, the Middle East & Africa Q1 y/y: +2% 64% 32% of sales of sales 36% of sales Asia Pacific Latin America Q1 y/y: +13% Emerging markets Q1 y/y: +10% Q1 y/y: +14% 12% 20% 36% of sales of sales of sales 13